April 2021

Maintenance Therapy With Olaparib Found To Result In Clinically Meaningful Improvement In OS In Women With Platinum-Sensitive, BRCA 1/2-Mutated, Relapsed Ovarian Cancer

Posted on April 20, 2021 by Womens Cancer Care

Cancer Therapy Advisor (4/19, Blevins Primeau) reports, “Maintenance therapy with olaparib was found to result in a clinically meaningful, but not statistically significant, improvement in overall survival compared with placebo among women with platinum-sensitive, BRCA 1/2-mutated, relapsed ovarian cancer, according to” a study. The findings were published in The Lancet Oncology. […]

Personalized Genomic Vaccine Appeared Safe, Induced Immunogenicity Among Patients With Different Cancers At High Risk For Recurrence

Posted on April 15, 2021 by Womens Cancer Care

Healio (4/13, Lawrence) reports that “a personalized genomic vaccine administered after standard-of-care adjuvant therapy appeared safe and induced immunogenicity among patients with different cancers at a high risk for recurrence, according to results of a phase 1 trial.” The research, “presented at the virtual American Association for Cancer Research Annual Meeting, also showed feasibility of developing the […]

Olaparib As Maintenance Therapy In Patients With Platinum-Sensitive Relapsed Ovarian Cancer, BRCA1/2 Mutations Following 2 Or More Prior Platinum Regimens Shows Trend Toward OS

Posted on April 7, 2021 by Womens Cancer Care

Cancer Network (4/5, Sternberg) reports, “A final analysis of the phase 3 SOLO2 trial (NCT01874353) examining olaparib (Lynarza) tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and BRCA1/2 mutations following 2 or more prior platinum regimens showed a trend toward overall survival (OS) superiority versus placebo maintenance.” The results were published in Lancet Oncology. […]

Surveillance Of CA-125 Alone May Be Used To Detect Disease Progression Of Advanced Ovarian Cancer Being Treated With Olaparib And Bevacizumab, Trial Results Show

Posted on April 1, 2021 by Womens Cancer Care

Cancer Network (3/31, Seymour) reports, “In patients with an abnormal CA-125 level at the beginning of frontline maintenance therapy, surveillance of CA-125 alone may be used to detect disease progression of advanced ovarian cancer being treated with olaparib (Lynparza) and bevacizumab (Avastin).” The “results were taken from an analysis of the phase 3 PAOLA-1 trial (NCT02477644) and […]